OptionsHouse

Options Trading News

October 5, 2012  Fri 12:18 PM CT

ZIOP: SEE CHART GET CHAIN FIND STRATEGIES
Ziopharm Oncology is expected to release key drug data by the end of the year, and traders are looking for good news.

optionMONSTER's Heat Seeker tracking system detected the purchase of more than 5,000 April 7 calls for $0.65 to $0.80. Volume was more than 45 times previous open interest at the strike.

Those buyers have now locked in a $7 purchase price on the company, whose Palifosfamide cancer drug is undergoing Phase 3 trials. The stock could rip higher if the results are positive, causing those calls to generate major leverage.

If the data misses expectations, however, ZIOP could fall sharply. Owning calls rather than shares limits that risk and is more effective than picking arbitrary stop-loss levels.

This is especially useful because the drug-trial data will probably be released outside of market hours, potentially causing a price gap during extended trading. (See our Education for more ideas on how options can be used to manage risk.)

ZIOP is up 0.59 percent to $5.11 afternoon trading and has been grinding higher since the first half of 2009. More than 5,300 contracts have traded in the name so far today, compared with about 1,000 in a typical session. Calls account for a bullish 98 percent of the volume.
Share this article with your friends


Related Stories

ZIOP

Ziopharm attracts heavy call buying

February 9, 2016

The cancer-drug developer is down 62 percent in the last three months, but March call buyers are looking for a rebound.

OptionsHouse

Premium Services

Upcoming Webinar:

Using Options For Income

http://bit.ly/1nY1OKA

Jon Najarian and Adam Mesh of Options Wealth Machine discuss a detailed strategy utilizing credit spreads to generate income, and how any level of trader can use this simple trading technique.

Education & Strategy

Sweet Spot Exceptions

As discussed last week, when using the Stock Replacement Strategy to replace a stock position to trade direction, we want to use an option that has very similar characteristics to the stock. We talked about using the deep in-the-money, 80 to 85 delta option that is similar in the Greeks and has relatively little extrinsic value which tends to work against us in stock directional trading.

View more education articles »